Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG

뉴스 본문을 불러오고 있어요.

Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG | 웨이프 WAPE

Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIG

기사 요약

관련 종목

댓글 —